EICHORCondition: Performance Anxiety · Sponsor: Vanda Pharmaceuticals
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with performance anxiety.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Vanda Investigational Site | Tempe, Arizona, United States | — |
| Vanda Investigational Site | Beverly Hills, California, United States | — |
| Vanda Investigational Site | Garden Grove, California, United States | — |
| Vanda Investigational Site | San Jose, California, United States | — |
| Vanda Investigational Site | Torrance, California, United States | — |
| Vanda Investigational Site | Orlando, Florida, United States | — |
| Vanda Investigational Site | Boston, Massachusetts, United States | — |
| Vanda Investigational Site | North Dartmouth, Massachusetts, United States | — |
| Vanda Investigational Site | Las Vegas, Nevada, United States | — |
| Vanda Investigational Site | Berlin, New Jersey, United States | — |
| Vanda Investigational Site | New York, New York, United States | — |
| Vanda Investigational Site | Staten Island, New York, United States | — |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04800237